Gasparini M, Lombardi F, Rottoli L, Ballerini E, Morandi F
Pediatric Section, Istituto Nazionale Tumori, Milan, Italy.
J Clin Oncol. 1988 Mar;6(3):491-4. doi: 10.1200/JCO.1988.6.3.491.
Twelve children younger than 16 years affected by undifferentiated nasopharyngeal carcinoma (NPC) with advanced primary tumor (T3, T4) were treated with chemotherapy consisting of Adriamycin (ADM [doxorubicin; Adria Laboratories, Columbus, OH]), vincristine (VCR), and cyclophosphamide (CYC), and radiotherapy. Preradiation chemotherapy produced partial responses in eight of ten evaluable patients. Eleven of 12 patients achieved a complete response following radiotherapy. The actuarial 3-year continuous relapse-free survival (CRFS) was 75%. This represents a significant improvement when compared with the 8% rate obtained in a previous series of patients treated with radiotherapy either with or without adjuvant CYC.
12名16岁以下患有未分化鼻咽癌（NPC）且原发肿瘤晚期（T3、T4）的儿童接受了由阿霉素（ADM[多柔比星；阿德里亚实验室，俄亥俄州哥伦布市]）、长春新碱（VCR）和环磷酰胺（CYC）组成的化疗及放射治疗。放疗前化疗使10名可评估患者中的8名产生了部分缓解。12名患者中有11名在放疗后达到完全缓解。3年实际持续无复发生存率（CRFS）为75%。与之前一组接受放疗（无论是否联合辅助CYC）的患者所获得的8%的比率相比，这代表了显著的改善。
